Lung cancer (solid tumor): cross-border specialty drug access for international patients

Quick orientation

Lung cancer accounts for approximately 2.5 million new cases per year globally (Globocan 2022). Non-small cell lung cancer (NSCLC) is the most common subtype.

Typical age of onset. Most commonly in adults aged 50 and older; younger patients with driver-mutation-positive disease are increasingly recognized.

Severity tiers. Severity depends on stage and molecular profile.

Why specialty drugs for Lung cancer (solid tumor) are hard to access internationally

Multiple molecularly-targeted therapies for EGFR, ALK, ROS1, KRAS G12C, MET, HER2, RET, BRAF, and NTRK have been FDA-approved. Several newer agents are not yet broadly registered internationally, and access to molecular profiling is also uneven.

Treatments approved by the FDA

• Krazati (adagrasib) — FDA approval: 2022. Mechanism: KRAS G12C inhibitor. Route: Oral twice daily. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan.
• Augtyro (repotrectinib) — FDA approval: 2023. Mechanism: ROS1 and TRK inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 260,000 per year. Country pricing: UAE · Saudi Arabia · Qatar · Kuwait · Egypt.
• Lazcluze (lazertinib) — FDA approval: 2024. Mechanism: Third-generation EGFR TKI. Route: Oral once daily. US WAC ballpark: Approximately USD 200,000 per year.
• Rybrevant (amivantamab-vmjw) — FDA approval: 2021. Mechanism: Bispecific EGFR-MET antibody. Route: Intravenous infusion. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: Saudi Arabia · Bahrain.
• Hernexeos (zongertinib) — FDA approval: 2025. Mechanism: HER2 exon 20 insertion-targeted TKI. Route: Oral. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: Saudi Arabia · India · Kuwait · Egypt · Jordan · Bahrain.
• Ibtrozi (taletrectinib) — FDA approval: 2025. Mechanism: ROS1 inhibitor. Route: Oral. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: Saudi Arabia · Jordan · Lebanon.
• Emrelis (telisotuzumab vedotin) — FDA approval: 2025. Mechanism: MET-directed antibody-drug conjugate. Route: Intravenous infusion. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: India · Qatar.
• Ensacove (ensartinib) — FDA approval: 2024. Mechanism: ALK inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: Qatar · Oman.
• Zegfrovy (sunvozertinib) — FDA approval: 2025. Mechanism: EGFR exon 20 insertion-targeted TKI. Route: Oral. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: Qatar · Bahrain · Lebanon.
• Datroway (datopotamab deruxtecan) — FDA approval: 2025. Mechanism: TROP2-directed antibody-drug conjugate for advanced NSCLC. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: UAE · Saudi Arabia · India · Kuwait · Egypt.
• Tepkinly (epcoritamab; representing bispecific class) — FDA approval: 2023. Mechanism: CD3xCD20 bispecific (lymphoma label; bispecific representative for biologic class). Route: Subcutaneous injection. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: Saudi Arabia · India · Kuwait · Egypt.

Cross-border pathways used for Lung cancer (solid tumor)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm NSCLC subtype and full molecular profile.
• Where local profiling is unavailable, coordinate sample referral to qualified labs.
• Document prior systemic therapy.
• Watch for class-specific adverse events including interstitial lung disease and dermatologic reactions.
• Multidisciplinary thoracic oncology team co-manages.

Common questions

Which targeted therapy is right for my case?

Choice depends entirely on molecular profile and prior therapy. Your oncologist decides.

How is molecular testing handled?

Where local testing is unavailable, samples can be referred to qualified labs.

How long does shipment take?

Five to fifteen business days from prescription receipt.

Are these drugs registered in my country?

Registration varies. We confirm by destination.

What documents are required?

Oncologist's prescription, pathology with molecular profile, imaging, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Lung cancer (solid tumor), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Lung cancer (solid tumor)

Reserved for you.